ECP Immunomodulation Award 2024

Celebrating 30 Years of Therakos ECP Immunomodulation™ treating GvHD Patients

Advancing ECP Immunomodulation Investigator Award in Graft versus host disease:
Refining THERAKOS ECP Immunomodulation™

The Award

In 2024 we have reached a significant milestone in that Therakos ECP Immunomodulation^TM has been treating GvHD patients for 30 years. To recognise this fact and demonstrate our continued commitment to investigation the science of ECP this years award will focus on GvHD.

As in previous years, the 2024 award programme is intended to recognise and support young researchers or their institutions who are making a difference in advancing the knowledge around ECP Immunomodulation, in the EMEA region*, with one educational grant of €75,000. This year’s award programme supports research that investigates the overarching immunomodulatory role of ECP while harnessing the ability of each patient’s immune system to modulate dysregulated immune function in Graft versus Host disease.

Find out more about the past EIA winners and their research in advancing the knowledge around ECP Immunomodulation

Discover more

Criteria

The following types of projects will be considered:

Basic, translational or outcomes-based research (examples could include, but are not limited to, mechanistic questions, cell populations involved, the analysis of existing clinical data and/or corresponding patient reported outcomes and biomarker samples).
Collaborative projects, in the meaning that research could be carried out by the applicant in collaboration with multiple institutions. This is intended to encourage pan-European collaborations.

The Investigator Award Committee, consisting of a group of Medical Scientists employed by Mallinckrodt Pharmaceuticals, will select applications based on the above-mentioned criteria, judging specifically the novelty and feasibility of submitted projects. Please see all terms and conditions specified below.

Closing Date

Applications will be accepted from now until 1^st September.

The winner of the award will be notified by 20^th September.

How to apply

Submit your applications here

Submit Applications

*Austria, Belgium, Croatia, Cyprus, Czech Republic, Denmark, Egypt, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Jordan, Netherlands, Norway, Poland, Portugal, Saudi Arabia, Slovenia, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, United Kingdom.

Terms and Conditions

FAQs

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS^TM CELLEX^TM Photopheresis System is indicated for the administration of photopheresis. Please refer to the appropriate product labelling for a complete list of warnings and precautions.

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease.
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³.
Patients who have coagulation disorders or who have previously had a splenectomy.

Warnings and Precautions

THERAKOS^TM Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure. Safety in children has not been established.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS^TM Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

Please refer to the THERAKOS^TM CELLEX^TM Photopheresis System Operator Manual for a complete list of warnings and precautions.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Contraindications

Methoxsalen is contraindicated in:

Patients exhibiting idiosyncratic or hypersensitivity reactions to methoxsalen, psoralen compounds, or any of the excipients
Patients with co-existing melanoma, basal cell or squamous cell skin carcinoma
Patients who are pregnant, and sexually active men and women of childbearing potential unless adequate contraception is used during treatment
Patients with aphakia because of the significantly increased risk of retinal damage due to the absence of a lens

Warnings and Precautions

Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.
Safety in children has not been established.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Please refer to the THERAKOS^TM CELLEX^TMPhotopheresis System Operator Manual for a complete list of warnings, precautions and adverse events.

ECP Immunomodulation Award 2024

Celebrating 30 Years of Therakos ECP Immunomodulation™ treating GvHD Patients

Advancing ECP Immunomodulation Investigator Award in Graft versus host disease:Refining THERAKOS ECP Immunomodulation™